SCHEMBL4501189

SCHEMBL4501189

Cc1ccc2[nH]c(C(C3=C(O)C(c4ccccc4)CC3=O)c3ccccc3)c(CCN)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
MLKL Q8NB16 1/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP19A1 P11511 1/20 0.38
KIF11 P52732 2/20 0.38
KDM4E B2RXH2 2/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
HTR1D P28221 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTR7 P34969 1/20 0.36
HTR3A P46098 1/20 0.36
HTR6 P50406 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1379874 0.87 MTNR1A (0.49) MAPTLMNAHTTALDH1A1CYP19A1
SCHEMBL1376601 0.84 KIF11 (0.33) MAPTLMNAHTTALDH1A1CYP19A1
SCHEMBL4502874 0.78 DAO (0.39) MAPTLMNAHTTMLKLKMT2A
SCHEMBL1376806 0.77 MTNR1A (0.47) KMT2AALDH1A1KDM4ECYP1A2CYP3A4
SCHEMBL4759753 0.77 MTNR1A (0.64) ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL1379412 0.77 MTNR1A (0.59) KMT2AALDH1A1CYP19A1KDM4ECYP1A2
SCHEMBL4507265 0.77 MLKL (0.40) MAPTLMNAHTTMLKLKMT2A
SCHEMBL4500952 0.73 PIM1 (0.39) CYP19A1PIM1
SCHEMBL1378443 0.73 MTNR1A (0.47) KMT2ACYP19A1CYP1A2CYP3A4CYP2C9
SCHEMBL8239481 0.72 MTNR1A (0.51) LMNAKMT2AALDH1A1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612099-B2 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-03 US disclosed
US-7612099-B2 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-03 US disclosed
US-7612099-B2 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-03 US disclosed
EP-1957483-A1 NOVEL VINYLOGOUS ACIDS DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-08-20 EP disclosed
WO-2007063010-A1 NOVEL VINYLOGOUS ACIDS DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-07 WO disclosed
WO-2007063010-A1 NOVEL VINYLOGOUS ACIDS DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-07 WO disclosed
US-20070129421-A1 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. 2007-06-07 US disclosed
US-20070129421-A1 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. 2007-06-07 US disclosed
US-20070129421-A1 Vinylogous acid derivatives HOFFMANN-LA ROCHE INC. 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129421-A1 Vinylogous acid derivatives CMA1, TPSG1, TPSAB1 MAPT 4559/4885LMNA 2861/4885HTT 3379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.